On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
Senneville and Lipsky return with a measured rejoinder in Clinical Infectious Diseases (April 2026), arguing that the Lagrand trial shows the absence of evidence of superiority — not definitive equivalence — between ulcer-bed and bone biopsy for guiding antibiotic therapy in diabetic foot osteomyelitis.
A new protocol paper in Sensors describes a chatbot that doses walking like a drug for patients in diabetic foot remission.
A cost-effectiveness analysis of the DIAFOS trial shows that in-shoe plantar pressure-guided custom footwear saves over €8,000 per ulcer prevented — and adherent patients push the probability of cost-effectiveness to 94%. The economic case for prevention just got stronger.
Chronic wounds are biological computers stuck in a boot loop. Sharp debridement is Control-Alt-Delete — the histological reboot that converts a chronic wound back into an acute one. Only then can you run the apps.
A new systematic review finds that roughly one in three adults in remission after a healed diabetic foot ulcer develop a recurrent ulcer within 12 months — a risk comparable to several common cancers. Healing is the beginning of the next chapter, not the end of the story.
A recent study published in Diabetic Medicine, titled "Hotspots: Adherence in home foot temperature monitoring interventions for at‐risk feet with diabetes – A narrative review," explores the importance of home foot temperature monitoring (HFTM) for individuals with diabetes who are at risk for foot complications[1]. The study was conducted by our colleague Petra Jones and... Continue Reading →
